Cargando…

Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease

BACKGROUND: Stereotactic body radiation therapy (SBRT) as a form of noninvasive treatment that is becoming increasingly used to manage cancers with adrenal gland metastases. There is a paucity of data on safety and efficacy of this modality. The aim of the study was to evaluate the safety and effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Reshko, Leonid B., Gaskins, Jeremy T., Silverman, Craig L., Dunlap, Neal E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281902/
https://www.ncbi.nlm.nih.gov/pubmed/34277086
http://dx.doi.org/10.5603/RPOR.a2021.0055
_version_ 1783722909476323328
author Reshko, Leonid B.
Gaskins, Jeremy T.
Silverman, Craig L.
Dunlap, Neal E.
author_facet Reshko, Leonid B.
Gaskins, Jeremy T.
Silverman, Craig L.
Dunlap, Neal E.
author_sort Reshko, Leonid B.
collection PubMed
description BACKGROUND: Stereotactic body radiation therapy (SBRT) as a form of noninvasive treatment that is becoming increasingly used to manage cancers with adrenal gland metastases. There is a paucity of data on safety and efficacy of this modality. The aim of the study was to evaluate the safety and efficacy of adrenal gland SBRT in oligometastatic and oligoprogressive disease. MATERIALS AND METHODS: In this retrospective study, we performed a single-institution analysis of 26 adrenal lesions from 23 patients with oligometastatic or oligoprogressive disease treated from 2013 to 2019 with the goal of achieving durable local control. Palliative cases were excluded. Radiation dosimetry data was collected. Kaplan Meier product estimator and Cox proportional hazards regression analysis were used for statistical analysis. RESULTS: The median dose was 36 Gy in 3 fractions (range: 24–50 Gy and 3–6 fractions) with a median biologically effective dose (BED10) of 72 (range: 40–100). 1-year local control rate was 80% and median local control was not achieved due to a low number of failures. 1- and 2-year overall survival rates were 66% and 32%. Toxicity was mild with only one case of grade 2 nausea and no grade 3–5 toxicity. Higher neutrophil to lymphocyte ratio was associated with worse overall survival and a trend toward worse progression-free survival. In addition, worse performance status and lower BED10 were associated with worse survival. No such association could be shown for primary tumor location, histology, size or stage. CONCLUSION: Adrenal SBRT for oligometastatic or oligoprogressive disease is a safe and effective form of treatment.
format Online
Article
Text
id pubmed-8281902
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Via Medica
record_format MEDLINE/PubMed
spelling pubmed-82819022021-07-16 Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease Reshko, Leonid B. Gaskins, Jeremy T. Silverman, Craig L. Dunlap, Neal E. Rep Pract Oncol Radiother Research Paper BACKGROUND: Stereotactic body radiation therapy (SBRT) as a form of noninvasive treatment that is becoming increasingly used to manage cancers with adrenal gland metastases. There is a paucity of data on safety and efficacy of this modality. The aim of the study was to evaluate the safety and efficacy of adrenal gland SBRT in oligometastatic and oligoprogressive disease. MATERIALS AND METHODS: In this retrospective study, we performed a single-institution analysis of 26 adrenal lesions from 23 patients with oligometastatic or oligoprogressive disease treated from 2013 to 2019 with the goal of achieving durable local control. Palliative cases were excluded. Radiation dosimetry data was collected. Kaplan Meier product estimator and Cox proportional hazards regression analysis were used for statistical analysis. RESULTS: The median dose was 36 Gy in 3 fractions (range: 24–50 Gy and 3–6 fractions) with a median biologically effective dose (BED10) of 72 (range: 40–100). 1-year local control rate was 80% and median local control was not achieved due to a low number of failures. 1- and 2-year overall survival rates were 66% and 32%. Toxicity was mild with only one case of grade 2 nausea and no grade 3–5 toxicity. Higher neutrophil to lymphocyte ratio was associated with worse overall survival and a trend toward worse progression-free survival. In addition, worse performance status and lower BED10 were associated with worse survival. No such association could be shown for primary tumor location, histology, size or stage. CONCLUSION: Adrenal SBRT for oligometastatic or oligoprogressive disease is a safe and effective form of treatment. Via Medica 2021-06-09 /pmc/articles/PMC8281902/ /pubmed/34277086 http://dx.doi.org/10.5603/RPOR.a2021.0055 Text en © 2021 Greater Poland Cancer Centre https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
spellingShingle Research Paper
Reshko, Leonid B.
Gaskins, Jeremy T.
Silverman, Craig L.
Dunlap, Neal E.
Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
title Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
title_full Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
title_fullStr Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
title_full_unstemmed Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
title_short Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
title_sort stereotactic body radiation therapy (sbrt) of adrenal gland metastases in oligometastatic and oligoprogressive disease
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281902/
https://www.ncbi.nlm.nih.gov/pubmed/34277086
http://dx.doi.org/10.5603/RPOR.a2021.0055
work_keys_str_mv AT reshkoleonidb stereotacticbodyradiationtherapysbrtofadrenalglandmetastasesinoligometastaticandoligoprogressivedisease
AT gaskinsjeremyt stereotacticbodyradiationtherapysbrtofadrenalglandmetastasesinoligometastaticandoligoprogressivedisease
AT silvermancraigl stereotacticbodyradiationtherapysbrtofadrenalglandmetastasesinoligometastaticandoligoprogressivedisease
AT dunlapneale stereotacticbodyradiationtherapysbrtofadrenalglandmetastasesinoligometastaticandoligoprogressivedisease